It’s an exciting week for cancer drug development with the AACR-NCI-EORTC molecular targets meeting in Boston (Twitter: #Targets15) and the 2015 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD (Twitter: #SITC2015)
However, today’s news is the much anticipated release of the abstracts (apart from the late breakers and press program) for the 2015 American Society of Hematology (ASH) annual meeting (Twitter: #ASH15) that takes place in Orlando from December 5-8th. We’ll at the meeting for the blog.
There is so much great science at ASH, it’s really hard to do it justice – we’ve been known to spend most of the meeting in the poster halls…and until you see the data it’s impossible to provide detailed commentary or analysis.
However, there’s so much interest in the abstracts that for the benefit of our subs, I’ve highlighted several that caught my attention in what is a fast, real-time, top-line review while at SITC this morning.
This initial review covers two hot topics in cancer immunotherapy – CAR T cells and Checkpoint inhibitors.
Subscribers can login below or you can purchase access if you’d like to read our SITC and ASH conference coverage.